Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5296-5302

  Rose, Warren E ^a   Schulz, Lucas T ^b   Andes, David ^c   Striker, Rob ^c,e   Berti, Andrew D ^a   Hutson, Paul R ^a   Shukla, Sanjay K ^d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b University of Wisconsin Health   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d MARSHFIELD CLINIC   (United States)

^e WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; DAPTOMYCIN; OXACILLIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BLOOD CULTURE; CASE REPORT; CELL DAMAGE; CELL MEMBRANE FLUIDITY; COLONY FORMING UNIT; CREATININE CLEARANCE; DRUG EXPOSURE; ENDOCARDITIS; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DAPTOMYCIN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84866315707     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00797-12     Document Type: Article

References (31)

1. Akins RL, Rybak MJ. 2000. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob. Agents Chemother. 44:1925-1929. (Pubitemid 30422950)
2. Bayer AS, et al. 2000. In vitro resistance of Staphylococcus aureus to thrombin-induced platelet microbicidal protein is associated with alterations in cytoplasmic membrane fluidity. Infect. Immun. 68:3548-3553. (Pubitemid 30340456)
3. Belley A, et al. 2009. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob. Agents Chemother. 53: 918-925.
4. Blaser J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl A):125-130. (Pubitemid 15079556)
5. Chamberlain NR, et al. 1991. Correlation of carotenoid production, decreased membrane fluidity, and resistance to oleic acid killing in Staphylococcusaureus 18Z. Infect. Immun. 59:4332-4337.
6. Clinical and Laboratory Standards Institute. 2011. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 11th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Dhand A, et al. 2011. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin. Infect. Dis. 53:158-163.
8. Drusano GL. 2010. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin- resistant Staphylococcus aureus activity. J. Antimicrob. Chemother. 65(Suppl 4):iv33-iv9.
9. Dvorchik B, et al. 2004. Population pharmacokinetics of daptomycin. Antimicrob. Agents Chemother. 48:2799-2807. (Pubitemid 38989139)
10. Enright MC, et al. 2002. The evolutionary history of methicillin- resistant Staphylococcus aureus (MRSA). Proc. Natl. Acad. Sci. U. S. A. 99:7687-7692. (Pubitemid 34568752)
11. Entenza JM, Giddey M, Vouillamoz J, Moreillon P. 2010. In vitroprevention of the emergence of daptomycin resistance in Staphylococcusaureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin. Int. J. Antimicrob. Agents 35:451-456.
12. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS II. 2012. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J. Antimicrob. Chemother. 67: 1267-1270.
13. Jacqueline C, et al. 2011. Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptideintermediate Staphylococcus aureus. J. Antimicrob. Chemother. 66:863-866.
14. Jones T, et al. 2008. Failures in clinical treatment of Staphylococcus aureusinfection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemother. 52:269-278.
15. Koreen L, et al. 2004. spa typing method for discriminating among Staphylococcusaureus isolates: implications for use of a single marker to detect genetic micro- and macrovariation. J. Clin. Microbiol. 42:792-799. (Pubitemid 38222664)
16. Kullar R, et al. 2011. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 31:527-536.
17. Mishra NN, et al. 2011. Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides. Antimicrob. Agents Chemother. 55:526-531.
18. Mishra NN, et al. 2009. Analysis of cell membrane characteristics of invitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcusaureus. Antimicrob. Agents Chemother. 53:2312-2318.
19. Mukhopadhyay K, et al. 2007. In vitro susceptibility of Staphylococcusaureus to thrombin-induced platelet microbicidal protein-1 (tPMP-1) is influenced by cell membrane phospholipid composition and asymmetry. Microbiology 153:1187-1197. (Pubitemid 46605817)
20. Murillo O, et al. 2009. Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 4252-4257.
21. Patel D, et al. 2011. Mechanisms of in-vitro-selected daptomycin-nonsusceptibility in Staphylococcus aureus. Int. J. Antimicrob. Agents 38:442-446.
22. Peleg AY, et al. 2012. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS One 7:e28316. doi:10.1371/journal.pone.0028316.
23. Riccobene T, Jakate A, Rank D, Thye D. 2009. An open-label, pharmacokinetic, safety, and tolerability study of single-dose intravenous ceftaroline in subjects with end-stage renal disdaese on intermittent haemodialysis, abstr P1455. Abstr. 19th Eur. Congr. Clin. Microbiol. Infect. Dis., European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
24. Rose WE, et al. 2008. Daptomycin activity against Staphylococcus aureusfollowing vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 52:831-836. (Pubitemid 351358359)
25. Rose WE, Rybak MJ, Kaatz GW. 2007. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivosimulation using historical and current dosing strategies. J. Antimicrob. Chemother. 60:334-340. (Pubitemid 47243883)
26. Sakoulas G, et al. 2012. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 56:838-844.
27. Saravolatz LD, Stein GE, Johnson LB. 2011. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Clin. Infect. Dis. 52:1156-1163.
28. Steed M, Vidaillac C, Rybak MJ. 2011. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 55:3522-3526.
29. Steed ME, Vidaillac C, Rybak MJ. 2012. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 56:955-959.
30. Xiong YQ, Mukhopadhyay K, Yeaman MR, Adler-Moore J, Bayer AS. 2005. Functional interrelationships between cell membrane and cell wall in antimicrobial peptide-mediated killing of Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3114-3121. (Pubitemid 41060548)
31. Yang SJ, et al. 2010. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob. Agents Chemother. 54: 3161-3169.